Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Parkinson disease, cancer, and LRRK2: causation or association?

Bandmann O, Cookson MR.

Neurology. 2012 Mar 13;78(11):772-3. doi: 10.1212/WNL.0b013e318249f744. Epub 2012 Feb 8. No abstract available.

PMID:
22323745
2.

LRRK2 gene and tremor-dominant parkinsonism.

Haugarvoll K, Uitti RJ, Farrer MJ, Wszolek ZK.

Arch Neurol. 2006 Sep;63(9):1346-7. No abstract available.

PMID:
16966525
3.

The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.

Inzelberg R, Cohen OS, Aharon-Peretz J, Schlesinger I, Gershoni-Baruch R, Djaldetti R, Nitsan Z, Ephraty L, Tunkel O, Kozlova E, Inzelberg L, Kaplan N, Fixler Mehr T, Mory A, Dagan E, Schechtman E, Friedman E, Hassin-Baer S.

Neurology. 2012 Mar 13;78(11):781-6. doi: 10.1212/WNL.0b013e318249f673. Epub 2012 Feb 8.

PMID:
22323743
4.

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B, Aasly J, Inzelberg R, Hassin-Baer S, Friedman E, Ruiz-Martinez J, Marti-Masso JF, Orr-Urtreger A, Bressman S, Saunders-Pullman R.

JAMA Neurol. 2015 Jan;72(1):58-65. doi: 10.1001/jamaneurol.2014.1973.

5.

LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease.

Saunders-Pullman R, Barrett MJ, Stanley KM, Luciano MS, Shanker V, Severt L, Hunt A, Raymond D, Ozelius LJ, Bressman SB.

Mov Disord. 2010 Nov 15;25(15):2536-41. doi: 10.1002/mds.23314.

6.

Parkinson's disease and cancer: the unexplored connection.

Garber K.

J Natl Cancer Inst. 2010 Mar 17;102(6):371-4. doi: 10.1093/jnci/djq081. Epub 2010 Mar 9. No abstract available.

PMID:
20215596
7.

The importance of LRRK2 mutations in Parkinson disease.

Schapira AH.

Arch Neurol. 2006 Sep;63(9):1225-8. Review. No abstract available.

PMID:
16966498
8.

LRRK2 mutations and Parkinsonism.

Albrecht M.

Lancet. 2005 Apr 2-8;365(9466):1230. No abstract available.

PMID:
15811455
9.

Structural variation and the expanding genomic architecture of Parkinson disease.

Shulman JM.

JAMA Neurol. 2013 Nov;70(11):1355-6. doi: 10.1001/jamaneurol.2013.4263. No abstract available.

PMID:
24018918
10.

Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.

Gilsbach BK, Ho FY, Vetter IR, van Haastert PJ, Wittinghofer A, Kortholt A.

Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10322-7. doi: 10.1073/pnas.1203223109. Epub 2012 Jun 11.

11.

Patient-control association study of the Leucine-Rich repeat kinase 2 (LRRK2) gene in South African Parkinson's disease patients.

Bardien S, Blanckenberg J, van der Merwe L, Farrer MJ, Ross OA.

Mov Disord. 2013 Dec;28(14):2039-40. doi: 10.1002/mds.25637. Epub 2013 Sep 6. No abstract available.

12.

[LRRK2: a gene belonging to the ROCO family is implicated in the Parkinson's disease].

Lesage S, Leutenegger AL, Brice A.

Med Sci (Paris). 2005 Dec;21(12):1015-7. French. No abstract available.

13.

LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?

Russo I, Bubacco L, Greggio E.

J Neuroinflammation. 2014 Mar 21;11:52. doi: 10.1186/1742-2094-11-52. Review.

14.

LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.

Elbaz A.

Lancet Neurol. 2008 Jul;7(7):562-4. doi: 10.1016/S1474-4422(08)70118-2. Epub 2008 Jun 6. No abstract available.

PMID:
18539536
15.

Lrrk2 in the limelight!

Farrer MJ.

Neurology. 2007 Oct 30;69(18):1732-3. No abstract available.

PMID:
17967990
16.

LRRK2 mutations and Parkinsonism.

Toft M, Mata IF, Kachergus JM, Ross OA, Farrer MJ.

Lancet. 2005 Apr 2-8;365(9466):1229-30. No abstract available.

PMID:
15811454
17.

Re: LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.

Bonifati V, Wu-Chou YH, Schweiger D, Fonzo AD, Lu CS, Oostra B.

Neurology. 2008 Jun 10;70(24):2348; author reply 2348-9. doi: 10.1212/01.wnl.0000317005.06662.01. No abstract available.

PMID:
18541891
18.

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson VL, Dawson TM.

Nat Med. 2010 Sep;16(9):998-1000. doi: 10.1038/nm.2199. Epub 2010 Aug 22.

19.

Leucine-rich repeat kinase 2 for beginners: six key questions.

Kett LR, Dauer WT.

Cold Spring Harb Perspect Med. 2012 Mar;2(3):a009407. doi: 10.1101/cshperspect.a009407. Review.

20.

Low disease risk in relatives of north african lrrk2 Parkinson disease patients.

Troiano AR, Elbaz A, Lohmann E, Belarbi S, Vidailhet M, Bonnet AM, Lesage S, Pollak P, Cazeneuve C, Borg M, Feingold J, Dürr A, Tazir M, Brice A; French Parkinson Disease Genetic Study Group.

Neurology. 2010 Sep 21;75(12):1118-9. doi: 10.1212/WNL.0b013e3181f39a2e. No abstract available.

PMID:
20855856

Supplemental Content

Support Center